Shifting business models need transformational leadership.
Life sciences contribute to improve health and quality of life of the population and ensure economic prosperity. The Swedish life science sector is defined by world-class research and research infrastructure, a health care system of high international standard, competitive industry, and world-leading innovation.
Swedish pharma and medtech companies are situated in a fast-moving globalized marked with increasing mobility of individuals, where the labour market and educational institutions are becoming more and more international, and competition is intensifying for people with cutting-edge expertise. During the recent years, the Life Sciences sector has faced strong levels of M&A activities, increasing the focus on smooth merger processes and solid corporate governance structures.
Amrop Sweden has solid experience from Leadership Advisory activities, Board Evaluations and C-suite placements for both public and private companies within the Pharma, Medtech and Biotech sector. Due to the global nature of the industry, our consultants work seamlessly across our global partnership to deliver outstanding consisting value on each assignment making sure that we bring the right expertise to the table.
We want to hear about your context and specific needs. Reach out to our industry experts to set up a meeting.
When Wisdom is Put to the Test
Leaders worldwide currently face careerdefining struggles to invoke wise decisionmaking during the COVID-19 pandemic. From the logistics of medical and food supply chains, to the subtleties of mass communication in a time of crisis, now more than ever, wise leadership is key to sustainable and legitimate organization-building. What happens when an executive steps into a top role in a new industry, or more difficult still, a high-profile crisis?
Pharma India 2030 - Trends and Talent | Executive Insights
India’s pharmaceutical industry is at a crossroads. Over the last few years, growth rate in Rupee terms has decelerated to mid-single digits. The rate of introduction of new products
has also undergone a marked slowdown. Meanwhile, whilst volume growth is also slowing slightly, it continues to be reasonably robust.
The UN’s 2030 Agenda for Sustainable Development is now
anchored in corporate CSR strategy worldwide. Not only is there an undeniable moral case for doing business sustainably, shareholders and other stakeholder groups are
actively scrutinizing the track record and plans of organizations before doing business with them, joining, or
investing in them. And yet the 2030 Agenda contains 17 Sustainable Development Goals and 169 targets. Tackling these is a daunting task.